Abstract:Poor tumor penetration and highly immunosuppressive tumor microenvironment are two major factors that limit the therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma (PDA). In this work, a redox-responsive gemcitabine (GEM)-conjugated polymer, PGEM, was employed as a tumor penetrating nanocarrier to co-load an immunomodulating agent (NLG919, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1) and a chemotherapeutic drug (paclitaxel (PTX)) for immunochemo combination therapy. The NLG919/PTX co-loaded micelles showed very small size of similar to 15 nm. In vivo tumor imaging study indicated that PGEM was much more effective than the relatively large-sized POEG-co-PVD nanoparticles (similar to 160 nm) in deep tumor penetration and could reach the core of the pancreatic tumor. PTX formulated in the PGEM carrier showed improved tumor inhibition effect compared with PGEM alone. Incorporation of NLG919 in the formulation led to a more immunoactive tumor microenvironment with significantly decreased percentage of Treg cells, and increased percentages of CD4(+) IFN gamma(+) T and CD8(+) IFN gamma(+) T cells. PGEM micelles co-loaded with PTX and NLG919 showed the best anti-tumor activity in pancreatic (PANCO2) as well as two other tumor models compared to PGEM micelles loaded with PTX or NLG919 alone, suggesting that codelivery of NLG919 and PTX via PGEM may represent an effective strategy for immunochemotherapy of PDA as well as other types of cancers. Statement of Significance In order to effectively accumulate and penetrate the PDA that is poorly vascularized and enriched with dense fibrotic stroma, the size of nanomedicine has to be well controlled. Here, we reported an immunochemotherapy regimen based on co-delivery of GEM, PTX and IDO1 inhibitor NLG919 through an ultra-small sized GEM-based nanocarrier (PGEM). We demonstrated that the PGEM carrier was effective in accumulating and penetrating into PDA tumors. Besides, PGEM co-loaded with PTX and NLG9 induced an improved anti-tumor immune response and was highly efficacious in inhibiting tumor growth as well as in prolonging the survival rate in PANC02 xenograft model. Our work represents a potential strategy for enhancing PDA tumor penetration and immunochemotherapy. (C) 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Biomimetic Nanoparticles Delivered Hedgehog Pathway Inhibitor to Modify Tumour Microenvironment and Improved Chemotherapy for Pancreatic Carcinoma

Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer

Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer

Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy

A biomimetic nanodrug for enhanced chemotherapy of pancreatic tumors.

Tumor Microenvironment Modulation by Cyclopamine Improved Photothermal Therapy of Biomimetic Gold Nanorods for Pancreatic Ductal Adenocarcinomas.

Near‐Infrared Responsive Membrane Nanovesicles Amplify Homologous Targeting Delivery of Anti‐PD Immunotherapy Against Metastatic Tumors

Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy.

Sequential Delivery of Nanoformulated Α-Mangostin and Triptolide Overcomes Permeation Obstacles and Improves Therapeutic Effects in Pancreatic Cancer.

Cyclopamine Treatment Disrupts Extracellular Matrix and Alleviates Solid Stress to Improve Nanomedicine Delivery for Pancreatic Cancer.

Smart Hypoxia-Responsive Transformable and Charge-Reversible Nanoparticles for the Deep Penetration and Tumor Microenvironment Modulation of Pancreatic Cancer.

Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy

Cyclopamine Disrupts Tumor Extracellular Matrix and Improves the Distribution and Efficacy of Nanotherapeutics in Pancreatic Cancer.

Hollow Cu2MoS4 Nanoparticles Loaded with Immune Checkpoint Inhibitors Reshape the Tumor Microenvironment to Enhance Immunotherapy for Pancreatic Cancer.

Plectin-1-targeted recognition for enhancing comprehensive therapy in pancreatic ductal adenocarcinoma

Triple Drugs Co-Delivered by a Small Gemcitabine-Based Carrier for Pancreatic Cancer Immunochemotherapy.

PD-1/PD-L1 Pathway and Angiogenesis Dual Recognizable Nanoparticles for Enhancing Chemotherapy of Malignant Cancer

Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer

Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy

A Tumor‐Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer

Membrane-camouflaged supramolecular nanoparticles for co-delivery of chemotherapeutic and molecular-targeted drugs with siRNA against patient-derived pancreatic carcinoma